Greenwich Lifesciences Inc Stock Price, News & Analysis

Greenwich LifeSciences (NASDAQ:GLSI) has received regulatory approval to expand its FLAMINGO-01 Phase III clinical trial to Portugal, joining existing trial locations in Spain, France, Germany, Italy, Poland, Romania, Ireland, and the US. The trial evaluates GLSI-100, an immunotherapy designed to prevent breast cancer recurrences.

Dr. Luís António Marques da Costa, Associate Professor of Medicine and Head of Clinical Translational Oncology Research Unit at the Institute of Molecular Medicine, will serve as Portugal's national principal investigator. According to recent data, Portugal reported 9,065 new breast cancer cases in 2022, accounting for 30% of all female cancers, with 2,211 deaths recorded.

The company is currently activating trial sites in Lisbon and evaluating additional locations in central and northern Portugal.

Greenwich LifeSciences (Nasdaq: GLSI) has announced the expansion of its Phase III FLAMINGO-01 clinical trial to Ireland, following regulatory approval. The trial evaluates GLSI-100, an immunotherapy designed to prevent breast cancer recurrences.

The expansion adds Ireland to the existing trial locations in Spain, France, Germany, Italy, Poland, Romania, and the US. According to European Cancer Information System data, Ireland reported 3,723 new breast cancer cases in 2022, representing 30% of all women's cancers, with 883 deaths.

Dr. Janice Walshe, a prominent member of Cancer Trials Ireland, will serve as the national principal investigator at St Vincent's University Hospital in Dublin.

Greenwich LifeSciences (NASDAQ:GLSI) announced that the FDA has granted Fast Track designation for GLSI-100, its immunotherapy treatment for HLA-A*02 breast cancer patients. This designation may accelerate drug approval through enhanced FDA communication and rolling review process.

The company's Phase IIb clinical trial demonstrated impressive results with an 80% or greater reduction in cancer recurrences over 5 years in HER2/neu 3+ patients. The treatment showed no serious adverse events and was well-tolerated across 146 treated patients. GLSI-100 achieved peak immunity at 6 months, with booster injections providing extended protection.

Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company, announced that Noble Capital Markets has initiated company-sponsored equity research coverage. The company is currently conducting the Phase III FLAMINGO-01 clinical trial to evaluate GLSI-100, their immunotherapy treatment designed to prevent breast cancer recurrences.

Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, announced plans to build its internal clinical trial management team for the Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy for breast cancer recurrence prevention.

The company aims to reduce dependency on Clinical Research Organizations (CROs) by hiring dedicated internal staff, which is expected to lower costs and increase efficiency in managing clinical trial operations. This strategic shift will enable Greenwich to handle multiple trials simultaneously, including potential expansion of HLA-A*02 patient trials and development of other in-licensed drug candidates.

Greenwich LifeSciences (NASDAQ:GLSI) has received regulatory approval to expand its Phase III clinical trial, FLAMINGO-01, into Romania. The trial, which evaluates GLSI-100 immunotherapy for breast cancer recurrence prevention, will now include Romanian sites in addition to approximately 150 approved sites across Spain, France, Germany, Italy, Poland, and the US.

Dr. Nicoleta Antone, Head of Breast Cancer Centre at the Chiricuta Institute of Oncology, will serve as the national principal investigator in Romania. The expansion targets a significant market, as Romania reported 12,861 new breast cancer cases in 2022, representing 28% of all female cancers, with 3,877 deaths recorded that year.

Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company developing GLSI-100 immunotherapy for breast cancer recurrence prevention, has announced updates regarding recent CEO interviews and corporate events. The company has made available several key interviews on its website, including appearances on Bloomberg TV, a fireside chat at the Noble Virtual Conference, and an interview on the Charles Schwab Network.

The company has maintained an active presence at major industry events, presenting their Flamingo-01 trial data through posters at multiple conferences including the San Antonio Breast Cancer Symposium, ESMO Breast Conference, and ASCO. GLSI has also participated in several investor conferences including the BIO CEO & Investor Conference, H.C. Wainwright BioConnect, and the Jefferies Global Healthcare Conference.

Greenwich LifeSciences (NASDAQ: GLSI) has provided an update on its Phase III FLAMINGO-01 clinical trial evaluating GLSI-100, an immunotherapy for breast cancer recurrence prevention. The company reported positive preliminary data trends in both HLA-A*02 and non-HLA-A*02 arms, with the latter being expanded to 250 patients in 2024.

The trial achieved its highest screening rate in Q1 2025, processing over 150 patients per quarter across 117 active sites (40 US and 77 EU locations). The company plans to activate 30 additional EU sites in 2025, with potential for 10 more, bringing the total to over 150 sites globally.

The trial has garnered participation from prominent US teaching hospitals including Yale, Johns Hopkins, and Harvard, along with major European academic networks in Spain (GEICAM), France (UCGB), Germany (GBG), and Italy (GIM). The company is also developing manufacturing and regulatory strategies for both US and European markets.

Greenwich LifeSciences (NASDAQ: GLSI) has reported positive preliminary immune response data from its FLAMINGO-01 Phase III clinical trial evaluating GLSI-100, an immunotherapy for breast cancer recurrence prevention. The data shows increasing immune responses over time in both HLA-A*02 and non-HLA-A*02 patient arms.

Key findings include baseline immune response to GP2 before treatment and increasing response with vaccinations through months 4-6, consistent with Phase IIb trial results. The company has filed patent claims for non-HLA-A*02 patients, potentially doubling eligible patients to 88,000 annually in the US and Europe, with market potential of $8-10 billion per year.

Previous Phase IIb trial demonstrated an 80% or greater reduction in cancer recurrences over 5 years in HER2/neu 3+ patients treated with GLSI-100. The company is considering adding a randomized placebo arm for non-HLA-A*02 patients, effectively creating a second pivotal Phase III trial.